FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Saliva and Salivary Gland Dysfunction

Xeomin (incobotulinumtoxinA) (by Merz Pharmaceutical), Approved July 2010
For the treatment of cervical dystonia and blepharospasm

Sarcoma

Yondelis (trabectedin) (by Janssen), Approved October 2015
For the treatment of liposarcoma or leiomyosarcoma

Scar Tissue

Seprafilm (by Genzyme), Approved August 1996
Treatment for the reduction of scar tissue as a result of abdominal or pelvic surgery

Schizophrenia and Schizoaffective Disorders

Abilify (aripiprazole) (by Bristol-Myers Squibb, Otsuka America Pharmaceutical), Approved November 2002
Oral drug for the treatment of schizophrenia

Aristada (aripiprazole lauroxil) extended-release injectable (by Alkermes), Approved October 2015
For the treatment of schizophrenia

Fanapt (iloperidone) (by Vanda), Approved May of 2009
For the treatment of schizophrenia

Geodon (ziprasidone mesylate) (by Pfizer), Approved June 2002
To control agitated behavior and psychotic symptoms in schizophrenia patients

Invega (paliperidone) (by Janssen Pharmaceuticals), Approved December 2006
For the treatment of schizophrenia

Latuda (lurasidone) (by Sunovion), Approved October 2010
For the treatment of schizophrenia

Rexulti (brexpiprazole) (by Otsuka), Approved July 2015
For the treatment of depression and schizophrenia

Risperdal Oral Formulation (by Janssen Pharmaceuticals), Approved July 1996
Treatment for schizophrenia

Saphris (asenapine) (by Schering-Plough), Approved August of 2009
For the treatment of schizophrenia and manic or mixed bipolar 1 episodes

Vraylar (cariprazine) (by Allergan), Approved September 2015
For the treatment of schizophrenia and bipolar disorder

Ziprasidone (ziprasidone hydrochloride) (by Pfizer), Approved February 2001
Oral capsule for the treatment of schizophrenia

Seborrhea

Eskata (hydrogen peroxide) (by Aclaris Therapeutics), Approved December 2017
For the treatment of seborrheic keratoses

Seborrheic Dermatitis

Eskata (hydrogen peroxide) (by Aclaris Therapeutics), Approved December 2017
For the treatment of seborrheic keratoses

Seizure Disorders

Aptiom (eslicarbazepine acetate) (by Sunovion Pharmaceuticals), Approved November 2013
For the adjunctive treatment of partial-onset seizures

Banzel (rufinamide) (by Elan Pharmaceuticals), Approved November 2008
For the treatment of seizures associated with Lennox-Gastaut syndrome in pediatrics and adults

Briviact (brivaracetam) (by UCB), Approved February 2016
For the treatment of partial onset seizures related to epilepsy

Carbatrol (by Elan Pharmaceuticals), Approved September 1997
Treatment for epileptic seizures and trigeminal neuralgia

Carnexiv (carbamazepine) (by Lundbeck), Approved October 2016
replacement therapy when oral administration is not feasible, in adults with seizures

Clonazepam (by Watson Pharmaceuticals), Approved January 1998
Generic equivalent of Klonopin

Diacomit (stiripentol) (by Biocodex), Approved August 2018
For the treatment of seizures associated with Dravet syndrome

Epidiolex (cannabidiol) (by GW Pharmaceuticals), Approved June 2018
For the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome

Fycompa (perampanel) (by Eisai), Approved October 2012
For the treatment of partial-onset seizures with or without secondarily generalized seizures; tonic-clonic seizures

Keppra (by UCB), Approved November 1999
Levetiracetam tablets for adjunctive treatment of partial onset seizures in adults with epilepsy

Nayzilam (midazolam) (by UCB), Approved May 2019
For the treatment of intermittent, stereotypic episodes of frequent seizure activity

Neurontin (gabapentin) oral solution (by Parke-Davis), Approved March 2000
Treatment of partial seizures in adults with epilepsy

Onfi (clobazam) (by Lundbeck), Approved October 2011
For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome

Oxtellar XR (oxcarbazepine extended release) (by Supernus Pharmaceuticals), Approved October 2012
For the adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age

Potiga (ezogabine) (by Valeant Pharmaceuticals), Approved June 2011
For the treatment of partial-onset seizures

Qudexy XR (topiramate) (by Upsher-Smith Laboratories), Approved March 2014
For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome

Sabril (vigabatrin) (by Lundbeck), Approved August 2009
For the treatment of infantile spasms and complex partial seizures

Stavzor (valproic acid delayed release) (by Banner Pharmacaps), Approved July 2008
For the treatment of bipolar manic disorder, seizures and migraine headaches

Tegretol XR (carbamazepine) (by Ciba-Geigy), Approved May 1996
Anti-epileptic treatment

Topamax (topiramate) (by Ortho-McNeil Pharmaceutical), Approved January 1997
Treatment for partial onset seizures

Trileptal (oxcarbazepine) Tablets (by Novartis), Approved January 2000
Approved for use as adjunctive therapy in the treatment of partial seizures in children (monotherapy for adults)

Trokendi XR (topiramate) (by Supernus Pharmaceuticals), Approved August 2013
For the treatment of partial onset, tonic-clonic and Lennox-Gastaut Syndrome seizures

Vimpat (lacosamide) (by Schwarz Pharma), Approved October 2008
For the treatment of partial-onset seizures in adults with epilepsy

Zonegran (zonisamide) Capsules (by Dainippon Pharmaceutical), Approved March 2000
Adjunctive therapy for treatment of partial seizures in adults with epilepsy

Seizure Disorders (Pediatric)

Briviact (brivaracetam) (by UCB), Approved February 2016
For the treatment of partial onset seizures related to epilepsy

Diacomit (stiripentol) (by Biocodex), Approved August 2018
For the treatment of seizures associated with Dravet syndrome

Epidiolex (cannabidiol) (by GW Pharmaceuticals), Approved June 2018
For the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome

Fycompa (perampanel) (by Eisai), Approved October 2012
For the treatment of partial-onset seizures with or without secondarily generalized seizures; tonic-clonic seizures

Neurontin (gabapentin) oral solution (by Parke-Davis), Approved October 2000
For the treatment of partial seizures in pediatric patients three years of age and older

Onfi (clobazam) (by Lundbeck), Approved October 2011
For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome

Oxtellar XR (oxcarbazepine extended release) (by Supernus Pharmaceuticals), Approved October 2012
For the adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age

Potiga (ezogabine) (by Valeant Pharmaceuticals), Approved June 2011
For the treatment of partial-onset seizures

Qudexy XR (topiramate) (by Upsher-Smith Laboratories), Approved March 2014
For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome

Trileptal (oxcarbazepine) Tablets (by Novartis), Approved January 2000
Approved for use as adjunctive therapy in the treatment of partial seizures in children (monotherapy for adults)

Trokendi XR (topiramate) (by Supernus Pharmaceuticals), Approved August 2013
For the treatment of partial onset, tonic-clonic and Lennox-Gastaut Syndrome seizures

Sepsis and Septicemia

Cefazolin and Dextrose USP (by B Braun Medical), Approved July 2000
Respiratory tract infections

Giapreza (angiotensin II) (by La Jolla Pharmaceuticals), Approved December 2017
For the treatment of septic shock

Timentin (by SmithKline Beecham), Approved December 1997
Treatment for septicemia

Xigris (drotrecogin alfa [activated]) (by Eli Lilly), Approved November 2001
For the treatment of severe sepsis

Sexual Dysfunction

Addyi (flibanserin) (by Sprout Pharmaceuticals), Approved August 2015
For the treatment of premenopausal women with generalized hypoactive sexual desire disorder

Vyleesi (bremelanotide injection) (by AMAG Pharmaceuticals), Approved June 2019
For the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder

Sexually Transmitted Diseases (STDs)

Tindamax, tinidazole (by Presutti Laboratories), Approved May, 2004
For the treatment of microbial infections, including trichomoniasis, giardiasis, and amebiasis

Sezary Syndrome

Poteligeo (mogamulizumab-kpkc) (by Kyowa Kirin), Approved August 2018
For the treatment of mycosis fungoides or Sézary syndrome

Shingles

Horizant (gabapentin enacarbil) (by GlaxoSmithKline), Approved April 2011
For the treatment of restless legs syndrome

Horizant (gabapentin enacarbil) (by GlaxoSmithKline), Approved June 2012
For the treatment of postherpetic neuralgia

Neurontin (gabapentin) (by Pfizer), Approved May 2002
Oral treatment for the management of post-herpetic neuralgia (PHN)

Shingrix (Zoster Vaccine Recombinant, Adjuvanted) (by GlaxoSmithKline), Approved October 2017
For the prevention of herpes zoster (shingles)

Sickle Cell Disease

Endari (L-glutamine oral powder) (by Emmaus Life Sciences), Approved July 2017
For the treatment of sickle cell disease

Sinus Infections

Augmentin (amoxicillin/clavulanate) (by SmithKline Beecham), Approved February 1996
Treatment for infections involving drug-resistant bacteria

Avelox I.V. (moxifloxacin hydrochloride) (by Bayer), Approved November 2001
For adults with susceptible strains of bacterial infections

Cipro (ciprofloxacin HCl) (by Bayer), Approved June 1997
Treatment for acute sinusitis

Dupixent (dupilumab) (by Regeneron Pharmaceuticals and Sanofi), Approved June 2019
For the treatment of chronic rhinosinusitis with nasal polyposis in adults

Sjogren's Syndrome

Evoxac (by SnowBrand Pharmaceuticals), Approved January 2000
For the treatment of symptoms of dry mouth in patients with Sjogren's Syndrome

Salagen Tablets (by MGI Pharma), Approved February 1998
Treatment for Sjogren's Syndrome

Skin Aging

Afinitor (everolimus) (by Novartis), Approved April 2012
For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex

Afinitor (everolimus) (by Novartis), Approved March 2009
For the treatment of renal cell carcinoma

Afinitor (everolimus) (by Novartis), Approved May 2011
For the treatment of advanced pancreatic neuroendocrine tumors

Jeuveau (prabotulinumtoxinA-xvfs) (by Evolus), Approved February 2019
For the improvement of glabellar lines

laViv (azficel-T) (by Fibrocell Science), Approved June 2011
For the improvement of nasolabial fold wrinkles in adults

Renova (tretinoin emollient cream) (by Johnson & Johnson), Approved December 1995
Treatment for facial wrinkles, brown spots, and surface roughness associated with chronic sun exposure

Skin Cancer

Bavencio (avelumab) (by EMD Serono/Pfizer), Approved March 2017
For the treatment of Merkel cell carcinoma

Erivedge (vismodegib) (by Genentech), Approved January 2012
For the treatment of basal cell carcinoma

Keytruda (pembrolizumab) (by Merck), Approved December 2018
For the treatment of Merkel cell carcinoma

Keytruda (pembrolizumab) (by Merck), Approved September 2014
For the treatment of unresectable or metastatic melanoma

Odomzo (sonidegib) (by Novartis), July 2015
For the treatment of locally advanced basal cell carcinoma

Picato (ingenol mebutate) gel (by LEO Pharma), Approved January 2012
For the treatment of actinic keratosis

Skin Cell Studies

Erivedge (vismodegib) (by Genentech), Approved January 2012
For the treatment of basal cell carcinoma

Kybella (deoxycholic acid) (by Kythera Biopharma), Approved April 2015
For the treatment of submental fat

Renova (tretinoin emollient cream) (by Johnson & Johnson), Approved December 1995
Treatment for facial wrinkles, brown spots, and surface roughness associated with chronic sun exposure

Skin Infections/Disorders

Afinitor (everolimus) (by Novartis), Approved April 2012
For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex

Afinitor (everolimus) (by Novartis), Approved March 2009
For the treatment of renal cell carcinoma

Afinitor (everolimus) (by Novartis), Approved May 2011
For the treatment of advanced pancreatic neuroendocrine tumors

Bactroban Cream (by SmithKline Beecham), Approved December 1997
Treatment for secondarily infected traumatic skin lesions

Baxdela (delafloxacin) tablets and injection (by Melinta Therapeutics), Approved June 2017
For the treatment of acute bacterial skin and skin structure infections

Botox Cosmetic (botulinum toxin type A) (by Allergan), Approved April 2002
For the temporary improvement in the appearance of glabellar lines (brow furrow)

Cosentyx (secukinumab) (by Novartis), Approved January 2015
For the treatment of plaque psoriasis

Dalvance (dalbavancin) (by Durata Therapeutics), Approved May 2014
For the treatment of acute bacterial skin and skin structure infections

Enstilar (calcipotriene and betamethasone dipropionate) (by LEO Pharmaceuticals), Approved October 2015
For the treatment of psoriasis

Firazyr (icatibant) (by Shire Pharmaceuticals), Approved August of 2011
For the treatment of acute attacks of hereditary angioedema

Imbruvica (ibrutinib) (by Pharmacyclics), Approved August 2017
For the treatment of chronic graft-versus-host disease

Lamisil Solution, 1% (by Novartis), Approved March 2001
Topical treatment for tinea (pityriasis) versicolor, althete's foot, jock itch, and ringworm

Moxidectin (by Medicines Development for Global Health), Approved June 2018
For the treatment of onchocerciasis (river blindness)

Nuzyra (omadacycline) (by Paratek Pharmaceuticals), Approved October 2018
For the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

Omnicef (by Warner-Lambert), Approved December 1997
Treatment against various bacterias

Orbactiv (oritavancin) (by The Medicines Company), Approved August 2014
For the treatment of acute bacterial skin and skin structure infections

Otezla (apremilast) (by Celgene), Approved September 2014
For the treatment of moderate to severe plaque psoriasis

Sivextro (tedizolid phosphate) (by Cubist Pharmaceuticals), Approved June 2014
For the treatment of acute bacterial skin and skin structure infections

Taltz (ixekizumab) (by Eli Lilly), Approved March 2016
For the treatment of plaque psoriasis and active psoriatic arthritis

Tremfya (guselkumab) (by Janssen Biotech), Approved July 2017
For the treatment of moderate-to-severe plaque psoriasis

Vibativ (telavancin) (by Theravance), Approved September 2009
For the treatment of complicated skin and skin structure infections

Xepi (ozenoxacin) (by Medimetriks), Approved December 2017
For the treatment of impetigo

Sleep Apnea Syndromes

Sunosi (solriamfetol) (by Jazz Pharmaceuticals), Approved March 2019
For the treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea

Sleep Disorders

Wakix (pitolisant) (by Bioprojet Pharma), Approved August 2019
For the treatment of excessive daytime sleepiness in adults with narcolepsy

Belsomra (suvorexant) (by Merck), Approved August 2014
For the treatment of insomnia

Hetlioz (tasimelteon) (by Vanda Pharmaceuticals), January 2014
For the treatment of non-24-hour sleep-wake disorder in the totally blind

Intermezzo (zolpidem tartrate sublingual tablet) (by Transcept Pharmaceuticals), Approved November 2011
For the treatment of insomnia

Sunosi (solriamfetol) (by Jazz Pharmaceuticals), Approved March 2019
For the treatment of excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea

Small Cell Lung Cancer

Keytruda (pembrolizumab) (by Merck), Approved June 2019
previously treated metastatic small cell lung cancer

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved August 2018
For the treatment of advanced small cell lung cancer

Tecentriq (atezolizumab) (by Genentech/Roche), Approved March 2019
For the treatment of extensive-stage small cell lung cancer

Smallpox

Tpoxx (tecovirimat) (by Siga Technologies), Approved July 2018
For the treatment of smallpox

Smoking Cessation

Chantix (varenicline) (by Pfizer), Approved May 2006
For the treatment of nicotine addiction

Generic Transdermal Nicotine Patch (by Sano), Approved October 1997
Generic equivalent of Habitrol

NicoDerm CQ (by SmithKline Beecham, Hoechst Marion Roussel, Alza), Approved August 1996
Treatment for smoking cessation

Nicorette (nicotine polacrilex) (by SmithKline Beecham), Approved February 1996
Over-the-counter aid in smoking cessation

Nicotrol nasal spray (by Pharmacia & Upjohn), Approved March 1996
Treatment for nicotine addiction

Nicotrol transdermal patch (by McNeil Consumer Products), Approved July 1996
Treatment for smoking cessation

Zyban Sustained-Release Tablets (by GlaxoSmithKline), Approved May 1997
Treatment for smoking cessation

Soft Tissue Sarcoma

Lartruvo (olaratumab) (by Eli Lilly), Approved October 2016
For the treatment of soft tissue sarcoma

Votrient (pazopanib) (by GlaxoSmithKline), Approved April 2012
For the treatment of soft tissue sarcoma

Votrient (pazopanib) (by GlaxoSmithKline), Approved October of 2009
For the treatment of renal cell carcinoma

Yondelis (trabectedin) (by Janssen), Approved October 2015
For the treatment of liposarcoma or leiomyosarcoma

Solid Tumors

Keytruda (pembrolizumab) (by Merck), Approved May 2017
For the treatment of microsatellite instability-high or mismatch repair deficient solid tumors and colorectal cancer

Turalio (pexidartinib) (by Daiichi Sankyo), Approved August 2019
For the treatment of symptomatic tenosynovial giant cell tumor

Vitrakvi (larotrectinib) (by Loxo Oncology), Approved November 2018
For the treatment of solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion

Spinal Cord Injuries

Lyrica (pregabalin) (by Pfizer), Approved December 2004
For the treatment of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia

Lyrica (pregabalin) (by Pfizer), Approved June 2012
For the treatment of neuropathic pain associated with spinal cord injury

Spinal Muscular Atrophy

Spinraza (nusinersen) (by Biogen), Approved December 2016
For the treatment of spinal muscular atrophy

Zolgensma (onasemnogene abeparvovec-xioi) (by Avexis), Approved May 2019
For the treatment of pediatrics <2 years of age with spinal muscular atrophy with bi-allelic mutations in the SMN1 gene

Squamous Cell Carcinoma

Libtayo (cemiplimab-rwlc) (by Regeneron Pharmaceuticals), Approved September 2018
For the treatment of cutaneous squamous cell carcinoma

Staphylococcal Infections

Sivextro (tedizolid phosphate) (by Cubist Pharmaceuticals), Approved June 2014
For the treatment of acute bacterial skin and skin structure infections

Staphylococcal Skin Infections

Baxdela (delafloxacin) tablets and injection (by Melinta Therapeutics), Approved June 2017
For the treatment of acute bacterial skin and skin structure infections

Dalvance (dalbavancin) (by Durata Therapeutics), Approved May 2014
For the treatment of acute bacterial skin and skin structure infections

Orbactiv (oritavancin) (by The Medicines Company), Approved August 2014
For the treatment of acute bacterial skin and skin structure infections

Sivextro (tedizolid phosphate) (by Cubist Pharmaceuticals), Approved June 2014
For the treatment of acute bacterial skin and skin structure infections

Xepi (ozenoxacin) (by Medimetriks), Approved December 2017
For the treatment of impetigo

Stem Cell Transplant

Defitelio (defibrotide sodium) (by Jazz Pharmaceuticals), Approved March 2016
For the treatment of hepatic veno-occlusive disease with renal or pulmonary dysfunction following HSCT

Stomach Discomfort

Akynzeo (netupitant and palonosetron) (by Helsinn), Approved October 2014
For the prevention of chemotherapy-induced nausea and vomiting

Sustol (granisetron) (by Heron Therapeutics), Approved August 2016
For the prevention of chemotherapy-induced nausea and vomiting

Stroke

Aggrenox (by Boehringer Ingelheim), Approved November 1999
Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke

Eliquis (apixaban) (by Bristol-Myers Squibb), Approved December 2012
For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation

Pradaxa (dabigatran etexilate mesylate) (by Boehringer Ingelheim), Approved October 2010
For the risk reduction of stroke and embolism due to atrial fibrillation

Savaysa (edoxaban) (by Daiichi Sankyo), Approved January 2015
For the treatment of deep vein thrombosis, pulmonary embolism and risk of stroke and embolism due to atrial fibrillation

Xarelto (rivaroxaban) (by Janssen Pharmaceuticals), Approved July 2011
For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery

Xarelto (rivaroxaban) (by Janssen Pharmaceuticals), Approved November 2011
For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation

Xarelto (rivaroxaban) (by Janssen Pharmaceuticals), Approved October 2018
To reduce the risk of major cardiovascular (CV) events in people with chronic coronary or peripheral artery disease

Substance Abuse

Lucemyra (lofexidine) (by US Worldmeds), Approved May 2018
For the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults

Surgery

Bridion (sugammadex) (by Merck), Approved December 2015
For the reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery

Omidria (phenylephrine and ketorolac injection) (by Omeros), Approved June 2014
For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain

Systemic Lupus Erythematosus

Benlysta (belimumab) (by GlaxoSmithKline), Approved March 2011
For the treatment of systemic lupus erythematosus